PMID- 34434345
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210827
IS  - 1923-4155 (Print)
IS  - 1923-4163 (Electronic)
IS  - 1923-4155 (Linking)
VI  - 11
IP  - 11
DP  - 2020 Nov
TI  - Successful Treatment of Allergic Bronchopulmonary Aspergillosis Using a 
      Combination of Inhaled Fluticasone Furoate/Vilanterol and Oral Voriconazole.
PG  - 348-351
LID - 10.14740/jmc3567 [doi]
AB  - Systemic corticosteroids are considered to be the standard treatment for allergic 
      bronchopulmonary aspergillosis (ABPA). However, there is controversy regarding 
      use of inhaled corticosteroid (ICS) therapy for ABPA. Here we report a case of 
      ABPA that was successfully treated with inhaled fluticasone furoate/vilanterol 
      (FF/VI) and oral voriconazole (VRCZ). The patient was a 62-year-old Japanese man 
      with bronchiectasis and diabetes mellitus who presented with fever, cough, and 
      purulent sputum. Computed tomography scans of the chest showed consolidation in 
      the left upper and lower lobes. Laboratory investigations revealed an abnormal 
      increase in the number of eosinophils (3,340/mm(3)) and elevated levels of 
      C-reactive protein (3.04 mg/dL) and serum immunoglobulin E (IgE) (763 U/mL). 
      Eight days after admission, he experienced a sudden attack of asthma. 
      Aspergillus-precipitating antibodies were positive and Aspergillus fumigatus was 
      detected in sputum culture. These results were consistent with a diagnosis of 
      ABPA, and he was started on inhaled FF/VI and oral VRCZ. Systemic corticosteroids 
      were not used because of the patient's history of diabetes mellitus and left 
      atrial thrombus. His symptoms and consolidation improved significantly after 
      treatment. He has not experienced an exacerbation for more than 3 years. In mild 
      cases of ABPA in which total IgE is relatively low, inhaled FF/VI in combination 
      with oral VRCZ can be considered as an alternative treatment to systemic 
      corticosteroids in patients with ABPA.
CI  - Copyright 2020, Nishimatsu et al.
FAU - Nishimatsu, Kanako
AU  - Nishimatsu K
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka 543-0035, Japan.
FAU - Minami, Seigo
AU  - Minami S
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka 543-0035, Japan.
FAU - Ikuta, Shoko
AU  - Ikuta S
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka 543-0035, Japan.
FAU - Ihara, Shoichi
AU  - Ihara S
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka 543-0035, Japan.
AD  - Department of Respiratory Medicine, Daini Osaka Police Hospital, 2-6-40 
      Karasuga-tuji, Tennoji-ku, Osaka 543-0042, Japan.
FAU - Komuta, Kiyoshi
AU  - Komuta K
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka 543-0035, Japan.
AD  - Department of Respiratory Medicine, Daini Osaka Police Hospital, 2-6-40 
      Karasuga-tuji, Tennoji-ku, Osaka 543-0042, Japan.
LA  - eng
PT  - Case Reports
DEP - 20200923
PL  - Canada
TA  - J Med Cases
JT  - Journal of medical cases
JID - 101551824
PMC - PMC8383500
OTO - NOTNLM
OT  - Allergic bronchopulmonary aspergillosis
OT  - Aspergillus fumigatus
OT  - Bronchial asthma
OT  - Bronchiectasis
OT  - Fluticasone furoate/vilanterol
OT  - Inhaled corticosteroids
OT  - Itraconazole
OT  - Voriconazole
COIS- None to declare.
EDAT- 2021/08/27 06:00
MHDA- 2021/08/27 06:01
PMCR- 2020/11/01
CRDT- 2021/08/26 06:12
PHST- 2020/08/18 00:00 [received]
PHST- 2020/08/29 00:00 [accepted]
PHST- 2021/08/26 06:12 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2021/08/27 06:01 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - 10.14740/jmc3567 [doi]
PST - ppublish
SO  - J Med Cases. 2020 Nov;11(11):348-351. doi: 10.14740/jmc3567. Epub 2020 Sep 23.